Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of rivoceranib plus best supportive care versus placebo plus best supportive care in advanced or metastatic gastric cancer
2016-003984-20Phase 3Completed
- Sponsor
- Elevar Therapeutics
- Start
- Mar 2017
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in gastric cancer (GC) and gastroesophageal junction adenocarcinoma comparing Rivoceranib plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Overall survival. Started Mar 2017; status: completed.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2016-003984-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-003984-20.